Healthcare refers to the field associated with maintaining or restoring patients’ health. These days’ Healthcare Industry falls into a lashing of discrete sub-sectors, and ancillary goods and services. Ranging from therapeutic equipment to medicinal drugs, medical tourism to sickness insurance, the Healthcare Market has been one of the most swiftly expanding sectors within the globe’s economic system.
Global Healthcare spending contributes close to 10% to the whole world’s GDP, though it varies noticeably with geography. Thus, the Western world’s average healthcare costs are far greater in contrast to those in the developing economies. North America alone is in charge of circa a half of the world’s overall spending on healthcare services. With budgets curtailments and growing costs, technology advances are increasingly taking a new meaning in the global Healthcare universe.
The research reports offer comprehensive insights into the market sizing, structure and dynamics of the Healthcare Industry based on various geographies, as well as in-depth market segmentation. The research reports incorporated in this Catalogue closely investigate the competition in the Healthcare Market, besides profiling countless market participants. Moreover, tomorrow's healthcare-related challenges are addressed, as well as projections into the future are provided in the research reports.
Publications found:
113,786
Sort by:
Competitor Analysis: IGF-1R Antagonists
US$ 275.00
... -1/R antagonists Small Molecule Multi-target IGF-1/R antagonists Biologics as Selective IGF-1/R antagonists Biologics as Dual IGF-1/R antagonists Corporate IGF-1R Antagonist R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise ...
June 2011
26 pages
INTERCELL - No Tangible Value!
US$ 90.00
... on sideline, as there is no catalyst in 2011-12 that could boost the stock. Intercell (ICLL) woes of 2010 became worse in 2011 chiefly due to the ...
June 2011
1 pages
Catalysts Driven Investment Opportunities
US$ 140.00
... ) in the Biotech sector. The table lists the drug related catalysts for the Rising Star or Mature Biotech companies, our expectations ... of the series, which we will keep releasing in a timely manner. The catalysts include outcome of Advisory Committee Meetings (only June), PDUFA dates ...
June 2011
4 pages
Dr Reddy's PARA IV Pipeline Analysis
US$ 350.00
Dr Reddys has pipeline of ~20 Para IVs having branded sales of ~$24b. Among its Para IV pipeline the confirmed opportunities (branded sales ~$11.2b) are Exelon, Propecia, Zyprexa (20 mg), ... Nexium, Lipitor and Geodon. We expect PAT of ~$185m from the Dr. Reddy’s Para IVs which is ~3% of the current market Cap.
June 2011
21 pages
Lupin's PARA IV Pipeline Analysis
US$ 350.00
Lupin has pipeline of ~34 products having branded sales of ~$16b. Among its Para IV pipeline most lucrative opportunities are very few like that of Geodon, ... and Asacol. On other hand there are some Para IVs ...
June 2011
28 pages
Para IV presentation
US$ 350.00
A macro study on Indian Pharma Para IV litigations – a part of our recently introduced web based application - PARA IV Plus™ . This will provide you with a broad but meaningful insight to the prevalence of Indian Pharmaceutical companies in the Para IV space
June 2011
9 pages
RANBAXY'S PARA IV PIPELINE ANALYSIS
US$ 350.00
Ranbaxy has a pipeline of ~19 Para IV challenges, of which 12 are FTF’s. The total branded sales of these drugs under Para IV challenge by Ranbaxy is approximately $25b. Most of these Para ... offer decent upside. We expect Ranbaxy to generate a cumulative PAT of ~$950m from these Para IV opportunities, which is ...
June 2011
22 pages
Tarcva - EURTAC Data positive: Threat to Iressa in Firstline NSCLC
US$ 140.00
... by 63 % compared to chemotherapy (9.7 m vs 5.2 m). Interim analysis of EURTAC trial showed that Tarceva improved the overall survival by 4 m (22.9 m ... vs 18.8 m) compared to cisplatin chemotherapy. The data poses threat to AZN’s Iressa as it has not demonstrated OS ... lines of EGFR positive advanced NSCLC.
June 2011
2 pages
DISHMAN - Back To Basics
US$ 90.00
We reiterate our Underperform rating on Dishman despite it’s higher than expected Q4 FY11 result. The result was ...
May 2011
5 pages
Lupin Looses Combivir – A Big Blow To An Already Weak FY12 Pipeline
US$ 140.00
... for generic Combivir (Lamivudine + Zidovudine). With this approval, Teva has been granted and Lupin has ... ), Teva will launch its generic in Q4CY11. Lupin will be able to enter only after the 180 ... all other generics as well. We reiterate our Underperform on Lupin with target price of Rs.360 on the back of (1) ...
May 2011
2 pages
China Health Management Survey Report, 2011
US$ 1,400.00
With the development of Chinese economy, improvement of living standards and intensified aging population, Chinese people have growing demand for health management. In China, many industries are activ...
May 2011
62 pages
Market Access Europe: It's Not Just About Price
US$ 795.00
“May you live in interesting times.” Considered a curse by some, the saying could also be a blessing—especially when it comes to the evolving world of market access in Europe. Given its complex geo-po...
May 2011
71 pages
Medicated Skin Care in Kazakhstan
US$ 990.00
... on high-priced medicines, such as medicated skin care. Changing perceptions of beauty have also made people less... Euromonitor International's Medicated Skin Care in Kazakhstan report offers a comprehensive guide ... and Allergy Remedies, Child-Specific Digestive Remedies, Child-Specific Medicated Skin Care, Cold Sore Treatments, Combination Products - Cough, Cold and Allergy ...
May 2011
24 pages
Healthcare IT Market in Emerging Economies (2010 - 2015)
US$ 5,650.00
... quality healthcare delivery by growing aging population, and increase in chronic disease patient population is driving the increased adoption of IT solutions in the emerging markets. The Healthcare IT markets in emerging economies is expected to grow from $5.3 billion in 2010 to $10.9 billion in 2015, at an estimated CAGR of 15.3% from 2010 to 2015. The hardware segment dominates the healthcare IT market in emerging ...
May 2011
259 pages
Global DNA & Gene Chip (Microarray) Market (2010 - 2015)
US$ 5,650.00
... the largest share – 98% – of the global DNA & gene chip market in 2010. Gene Expression currently forms the largest application market as gene expression products are used in a wide ... diagnostics, biodefense, and agriculture. While this application contributed 28% to the Global DNA & Gene Chip (microarray) market revenues in 2010, cancer diagnosis and treatment application ...
May 2011
331 pages
China Healthcare Sector Analysis
US$ 800.00
Single User PDF Format: US$ 800.00
Multi-User License: US$ 1,100.00
Hard Copy: US$ 900.00
CD-ROM: US$ 900.00 Chinese healthcare industry is entering into a new phase with the advanced...
April 2011
95 pages
South African Healthcare Market Analysis
US$ 1,000.00
Single User PDF Format: US$ 1,000.00
Multi-User License: US$ 1,600.00
Hard Copy: US$ 1,200.00
CD-ROM: US$ 1,200.00 South African Healthcare industry is one with a lot of scope, which i...
April 2011
75 pages
Women's Health Diagnostic Testing Markets
US$ 3,995.00
Even though slightly more than half of the US population is female, medical research historically has neglected the health needs of women, other than reproductive issues. However, during the past two...
April 2011
150 pages
Facial Rejuvenation Markets
US$ 3,500.00
Price (Single User PDF): US$ 3,500.00 Price (Global Site License): US$ 7,000.00 The aging of the population, namely the baby boomer demographic segment is driving the market for facial rejuvenation p...
April 2011
250 pages
Out of Pocket Healthcare Spending 2011
US$ 1,995.00
Price (Single User PDF): US$ 1,995.00 Price (Global Site License): US$ 3,990.00 The costs of health care products and services continue to rise briskly, significantly outpacing currently low inflatio...
April 2011
85 pages
US Oncologist Survey: Optimizing Treatment for Large Cell Lymphoma
US$ 500.00
... that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progressions reveal ... Barriers to optimal patient care Confidence in treatment Data has been synthesized to show all responses and direct quotes from the oncologists ...
April 2011
35 pages
US Oncologist Survey: Optimizing Treatment for Advanced Non-Hodgkin's Lymphoma
US$ 1,200.00
... . This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US oncologists on the treatment of specific patient types. Patient situations: Asymptomatic indolent lymphoma Elderly infirm patient with advanced follicular lymphoma Relapsed ...
April 2011
61 pages
Human Albumin and Factor Vlll (FVIII) Markets: An Analysis
US$ 800.00
... conditions such as liver disease and hemorrhagic stroke. Another significant factor in albumin demand has been growing needs from emerging markets like ... profiles major players in the albumin and Factor VIII market. Further, we have predicted the future growth of albumin and Factor VIII market by combining SPSS ...
April 2011
45 pages
Research Report on China's Ophthalmic Preparation Industry 2011-2012
US$ 2,200.00
In China, ophthalmic diseases mainly include cataract, glaucoma, ocular inflammations, xeroma, ocular fundus diseases, ocular trauma, PCO (posterior capsule opacification), etc., among which cataract...
April 2011
50 pages
Hospital Market in China 2011
US$ 1,950.00
... report is sent in 0-2 business days after order is placed. The Hospital Market in China is growing steadily and has huge potential to grow in the near ... market overview section which gives an insight into the overall healthcare scenario in China along with the growth of hospitals and share of hospital ownership ...
April 2011
36 pages
Competitor Analysis: Adenosine Receptor Agonists & Antagonists
US$ 287.00
... and development of novel adenosine receptor agonists & antagonists. In addition, the report lists company-specific R&D pipelines of adenosine receptor agonists & antagonists in R&D. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, ...
April 2011
26 pages
Global Contract Manufacturing Market Analysis
US$ 1,500.00
Single User PDF Format: US$ 1,500.00
Multi-User License: US$ 2,200.00
Hard Copy: US$ 1,700.00
CD-ROM: US$ 1,700.00 The global pharmaceutical contract manufacturing industry has registe...
March 2011
70 pages
E-detailing Trends
US$ 495.00
Are we witnessing the death of the salesman?
Figures from a 2009 survey of physicians suggests that might be the case. Just 17 percent of doctors say they want traditional, linear contact fr...
March 2011
34 pages
Medicated Skin Care - India
US$ 990.00
... in medicated skin care categories that saw single digit value growth in previous years. Moreover, the launch of small packsizes by Paras... Euromonitor International's Medicated Skin Care in India report ... and Allergy Remedies, Child-Specific Digestive Remedies, Child-Specific Medicated Skin Care, Cold Sore Treatments, Combination Products - Cough, Cold and Allergy ...
March 2011
34 pages
New Value Perceptions in Skin Care
US$ 2,000.00
... away from premium towards either super premium or ‘mastige’ prices. Euromonitor International's New Value Perceptions in Skin Care global briefing offers an insight into to the size and shape of the Skin Care market and highlights buzz topics, emerging geographies, categories and trends as ...
March 2011
50 pages
European Markets for Dental Computer Guided Surgery 2011
US$ 4,495.00
... imaging systems, particularly CBCT scanners and the proven effectiveness of computer guided surgery in dental implant procedures. This report covers the following ... and the United Kingdom. Within the European dental computer guided surgery market, companies such as Materialise Dental and Nobel lead the ...
March 2011
82 pages
Changing Consumer Demands Around Reformulation for Health: Prioritising Salt Reduction
US$ 2,000.00
... and what does it mean for the end consumer? Euromonitor International's Changing Consumer Demands Around Reformulation for Health: Prioritising Salt Reduction ... Wellness market; Pinpoint growth sectors and identify factors driving change; Understand the competitive environment, the market’s major players and ...
March 2011
43 pages
Weight Management - India
US$ 900.00
... in India, products and information were still hard to find in the regular retail and media channels for the majority of consumers over ... unable to invest in educating consumers and expanding... Euromonitor International's Weight Management in India report offers a comprehensive guide to the size and shape of ...
March 2011
32 pages
RNAi for Therapeutic Applications: Market Prospects 2011-2021
US$ 2,325.00
... of that R&D, helping you to assess technological and commercial opportunities in the RNAi field. We give a balanced appraisal. What products will establish the ... you to understand this emerging industry and its potential. RNAi for Therapeutic Applications: Market Prospects 2011-2021 shows you revenue trends ...
March 2011
152 pages
Statins: World Market Outlook 2011-2021
US$ 2,325.00
... making it easier for you to stay ahead in this market. Statins: World Market Outlook 2011-2021 shows you revenue trends, opportunities and ... atorvastatin, rosuvastatin, simvastatin, pravastatin, fluvastatin, pitavastatin and lovastatin products to 2021 You will learn how the patent expiries of Lipitor and ...
March 2011
150 pages
Competitor Analysis RNA Therapeutics in Clinical Development
US$ 561.00
... online work with the project data to print or export an individual report. Although there are only two approved and marketed RNA based ... CpG Oligonucleotides Corporate Clinical Stage RNA Therapeutics R&D Pipelines About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but ...
March 2011
